JP2007502264A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502264A5
JP2007502264A5 JP2006523062A JP2006523062A JP2007502264A5 JP 2007502264 A5 JP2007502264 A5 JP 2007502264A5 JP 2006523062 A JP2006523062 A JP 2006523062A JP 2006523062 A JP2006523062 A JP 2006523062A JP 2007502264 A5 JP2007502264 A5 JP 2007502264A5
Authority
JP
Japan
Prior art keywords
group
nhc
compound according
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006523062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502264A (ja
Filing date
Publication date
Priority claimed from GBGB0319124.4A external-priority patent/GB0319124D0/en
Application filed filed Critical
Publication of JP2007502264A publication Critical patent/JP2007502264A/ja
Publication of JP2007502264A5 publication Critical patent/JP2007502264A5/ja
Withdrawn legal-status Critical Current

Links

JP2006523062A 2003-08-14 2004-08-13 Ｈｍ７４ａ受容体アゴニストとしての２−置換安息香酸誘導体 Withdrawn JP2007502264A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0319124.4A GB0319124D0 (en) 2003-08-14 2003-08-14 Chemical compounds
PCT/GB2004/003528 WO2005016870A1 (en) 2003-08-14 2004-08-13 2-substituted benzoic acid derivatives as hm74a receptor agonists

Publications (2)

Publication Number Publication Date
JP2007502264A JP2007502264A (ja) 2007-02-08
JP2007502264A5 true JP2007502264A5 (enExample) 2007-09-13

Family

ID=28052522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523062A Withdrawn JP2007502264A (ja) 2003-08-14 2004-08-13 Ｈｍ７４ａ受容体アゴニストとしての２−置換安息香酸誘導体

Country Status (4)

Country Link
EP (1) EP1670749A1 (enExample)
JP (1) JP2007502264A (enExample)
GB (1) GB0319124D0 (enExample)
WO (1) WO2005016870A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
EP1663204B1 (en) * 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
EP1824812A4 (en) * 2004-11-23 2009-10-28 Merck & Co Inc AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
GB0503054D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503053D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
US20080221108A1 (en) * 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
CA2603757A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2611910A1 (en) * 2005-06-14 2006-12-21 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
EP1901731B1 (en) 2005-06-28 2011-03-02 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007017261A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
US20090258862A1 (en) * 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20110028462A1 (en) * 2005-09-20 2011-02-03 Colletti Steven L Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment
JP2009520820A (ja) * 2005-12-20 2009-05-28 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、前記化合物を含む組成物及び治療方法
US8633160B2 (en) 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP1976502B1 (en) * 2005-12-30 2011-08-03 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US20090062269A1 (en) * 2006-02-07 2009-03-05 Subharekha Raghavan Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
CA2648642A1 (en) * 2006-04-11 2007-10-25 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2008016676A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
KR100832750B1 (ko) 2006-12-08 2008-05-27 한국화학연구원 Ｎ-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물
WO2008069611A1 (en) * 2006-12-08 2008-06-12 Korea Research Institute Of Chemical Technology N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same
US8309534B2 (en) 2007-05-15 2012-11-13 Medical College Of Georgia Research Institute, Inc. Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancer
AU2008287435B2 (en) 2007-08-15 2013-05-16 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
EP2272822A4 (en) 2008-03-31 2012-01-18 Renascience Co Ltd PLASMINOG ACTIVATOR-1 HEMMER
ES2874063T3 (es) * 2009-03-31 2021-11-04 Renascience Inc Inhibidor del inhibidor-1 del activador del plasminógeno
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
WO2012034116A2 (en) * 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2013092786A1 (en) * 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
US10092537B2 (en) 2013-04-15 2018-10-09 Renascience Co., Ltd. Use for PAI-1 inhibitor
CN104418764B (zh) * 2013-09-11 2017-02-01 上海伊明化学科技有限公司 一种二氢燕麦酰基邻氨基苯甲酸d合成方法
ES2578377B1 (es) 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.
CN106511110B (zh) * 2016-10-25 2019-10-01 福州美乐莲生物科技有限公司 二氢燕麦生物碱d盐类化合物作为化妆品活性成分的应用及其合成方法
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3662908A1 (en) * 2018-12-04 2020-06-10 Consejo Superior de Investigaciones Cientificas (CSIC) Modulating compounds of kchip2 and its use for the treatment of cardiovascular pathologies
CN109553550B (zh) * 2018-12-29 2022-02-22 上海克琴科技有限公司 一种合成二氢燕麦生物碱的方法
CN112939803B (zh) * 2021-02-07 2023-07-18 郑州轻工业大学 一种二氢燕麦生物碱d的制备工艺
CN114478296B (zh) * 2022-02-14 2024-07-19 河南旭瑞新材料科技有限公司 一种二氢燕麦生物碱的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPS59122449A (ja) * 1982-12-28 1984-07-14 Kissei Pharmaceut Co Ltd 芳香族カルボン酸アミド誘導体の製造方法
JPS6097946A (ja) * 1983-11-01 1985-05-31 Ono Pharmaceut Co Ltd カルボキサミド誘導体
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5808144A (en) * 1995-11-27 1998-09-15 Teijin Limited Benzene derivatives
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
WO1999007670A1 (en) * 1997-08-05 1999-02-18 American Home Products Corporation Anthranilic acid analogs
JP2001513526A (ja) * 1997-08-05 2001-09-04 アメリカン・ホーム・プロダクツ・コーポレイション アントラニル酸類似体
CN1245380C (zh) * 1998-07-24 2006-03-15 帝人株式会社 邻氨基苯甲酸衍生物
JP2002529455A (ja) * 1998-11-09 2002-09-10 ジェームズ・ブラック・ファウンデーション・リミテッド ガストリンおよびコレシストキニン受容体リガンド類
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
CA2400264A1 (en) * 2000-02-15 2001-08-23 Teijin Limited Cancer remedy comprising anthranilic acid derivative as active ingredient
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung

Similar Documents

Publication Publication Date Title
JP2007502264A5 (enExample)
JP2007502263A5 (enExample)
JP2008509187A5 (enExample)
JP2015531773A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
RU2008106058A (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
JP2012236838A5 (enExample)
JP2001526220A5 (enExample)
WO2001025190A1 (en) Novel diarylamide derivatives and use thereof as medicines
JP2020075939A5 (enExample)
JP2010529203A5 (enExample)
RU2010129541A (ru) Карбоксил- или гидроксилзамещенные производные бензимидазола
JP2020533352A5 (enExample)
JP2007504173A (ja) リネゾリドのｉｖ型結晶
EP2919779A1 (en) Cannabinoid receptor mediating compounds
JP2010516702A5 (enExample)
JP2010516700A5 (enExample)
JP2020532550A (ja) リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物
EP3303325A1 (en) Cannabinoid receptor mediating compounds
JPWO2006059744A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
JP2022539126A (ja) ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用
JP2008508247A5 (enExample)
JPWO2001036402A1 (ja) 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP2008533063A5 (enExample)
JP2010504321A5 (enExample)
JP2010504322A5 (enExample)